A Trial Evaluating the Efficacy and Safety of HSK3486 Injectable Emulsion in Subjects Undergoing Fiberoptic Bronchoscopy
Status:
Completed
Trial end date:
2020-07-27
Target enrollment:
Participant gender:
Summary
This is a Multi-Center, Randomized, Double-Blind, Propofol-Controlled Phase III Clinical
Trial. Around 260 eligible subjects are planned to be enrolled and randomized in a 1:1 ratio
to either the HSK3486 arm or propofol arm. The main objective is to evaluate the efficacy of
HSK3486 vs. propofol for the induction of sedation/anesthesia in subjects undergoing
fiberoptic bronchoscopy.
Phase:
Phase 3
Details
Lead Sponsor:
Sichuan Haisco Pharmaceutical Group Co., Ltd Sichuan Haisco Pharmaceutical Group Co., Ltd.